181 related articles for article (PubMed ID: 19951711)
1. Amlodipine, a Ca2+ channel blocker, suppresses phosphorylation of epidermal growth factor receptor in human epidermoid carcinoma A431 cells.
Yoshida J; Ishibashi T; Yang M; Nishio M
Life Sci; 2010 Jan; 86(3-4):124-32. PubMed ID: 19951711
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of amlodipine, a Ca2+ channel blocker, on human epidermoid carcinoma A431 cells in vitro and in vivo.
Yoshida J; Ishibashi T; Nishio M
Eur J Pharmacol; 2004 May; 492(2-3):103-12. PubMed ID: 15178352
[TBL] [Abstract][Full Text] [Related]
3. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
Park SY; Yoon SJ; Freire-de-Lima L; Kim JH; Hakomori SI
Carbohydr Res; 2009 Aug; 344(12):1479-86. PubMed ID: 19559406
[TBL] [Abstract][Full Text] [Related]
4. G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells.
Yoshida J; Ishibashi T; Nishio M
Biochem Pharmacol; 2007 Apr; 73(7):943-53. PubMed ID: 17217918
[TBL] [Abstract][Full Text] [Related]
5. Growth-inhibitory effect of a streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor.
Yoshida J; Ishibashi T; Nishio M
Cancer Res; 2001 Aug; 61(16):6151-7. PubMed ID: 11507066
[TBL] [Abstract][Full Text] [Related]
6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 inhibits the growth of human laryngeal squamous cell carcinoma and down regulates EGFR-MAPKs signaling pathway.
Gu D; Li H; Wang Z; Chen Q; Jiang J; Zhu H
Laryngoscope; 2007 Oct; 117(10):1782-9. PubMed ID: 17906498
[TBL] [Abstract][Full Text] [Related]
9. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
10. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-1 acts as a tumor suppressor by down-regulating epidermal growth factor receptor-mitogen-activated protein kinase signaling pathway in pancreatic carcinoma cell lines.
Han F; Gu D; Chen Q; Zhu H
Pancreas; 2009 Oct; 38(7):766-74. PubMed ID: 19893453
[TBL] [Abstract][Full Text] [Related]
13. Regulation by ceramide of epidermal growth factor signal transduction and mitogenesis in cell lines overexpressing the growth factor receptor.
Gallardo G; Tabraue C; Quintana J; López-Blanco F; Cabrera J; Díaz R; Estévez F; Ruiz de Galarreta CM; Fanjul LF; Santana P
Cell Mol Biol (Noisy-le-grand); 2000 Nov; 46(7):1305-12. PubMed ID: 11075960
[TBL] [Abstract][Full Text] [Related]
14. Suppression of epidermal growth factor receptor signaling by protein kinase C-alpha activation requires CD82, caveolin-1, and ganglioside.
Wang XQ; Yan Q; Sun P; Liu JW; Go L; McDaniel SM; Paller AS
Cancer Res; 2007 Oct; 67(20):9986-95. PubMed ID: 17942932
[TBL] [Abstract][Full Text] [Related]
15. Expression of functional epidermal growth factor receptors in a human hematopoietic cell line.
Oval J; Hershberg R; Gansbacher B; Gilboa E; Schlessinger J; Taetle R
Cancer Res; 1991 Jan; 51(1):150-6. PubMed ID: 1703031
[TBL] [Abstract][Full Text] [Related]
16. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal growth factor receptor monoclonal antibodies affecting signal transduction.
Reins HA; Steinhilber G; Freiberg B; Anderer FA
J Cell Biochem; 1993 Feb; 51(2):236-48. PubMed ID: 8382707
[TBL] [Abstract][Full Text] [Related]
18. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor activates phospholipase C in rat hepatocytes via a different mechanism from that in A431 or rat1hER cells.
Liang M; Garrison JC
Mol Pharmacol; 1992 Nov; 42(5):743-52. PubMed ID: 1435749
[TBL] [Abstract][Full Text] [Related]
20. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
